



## **MADRID EASL CLINICAL SCHOOL OF HEPATOLOGY**

### **CLINICAL DILEMMAS IN CIRRHOSIS: AN APPROACH FROM THE EVIDENCE TO THE DECISION**

7–8 July 2023

#### **SCIENTIFIC PROGRAM**

##### **COURSE ORGANIZERS**

Agustín Albillos, MD, PhD  
Rosa Martín-Mateos, MD, PhD  
Javier Zamora, MD, PhD  
Rafael Bañares, MD, PhD  
José Luis Calleja, MD, PhD

##### **INVITED FACULTY**

Thomas Reiberger, MD, PhD

##### **FACULTY HEPATOLOGY**

Luis Téllez, MD, PhD  
Enrique Rodríguez de Santiago, MD, PhD  
Ana García García de Paredes, MD, PhD  
Course organizers

##### **OTHER FACULTY**

Javier Zamora, MD, PhD (Course organizer)  
Methodology researchers TBD

##### **VENUE**

Hospital Ramón y Cajal, Universidad de Alcalá, Madrid, Spain

## PRELIMINARY PROGRAMME OVERVIEW

### DAY 1

08:30–09:00	Registration - Meeting point
09:00–09:30	Welcome and introduction to the school format
09:30–11:15	Introduction to focus on the clinical problems by the clinical Faculty* (5 short lectures on the clinical cases topics, 15 min each)
11:15–11:45	Coffee break
12:00–13:30	Methodology lectures by expert faculty on critical appraisal of evidence (4 short lectures, 20 min, on identifying/formulating questions, critical approach to different study designs, grading)**
13:30–14:45	Group designation and tutor assignment***
14:45–14:30	Lunch
14:30–18:00	Small group sessions: Presentation of clinical problems.; identification of questions and search of evidence; critical appraisal of evidence; formulation and grading of recommendations
18:00–18:30	Wrap-up of the groups

\* Talks on the clinical controversies by clinical course organizers plus Luis Téllez

\*\* Methodology talks by Javier Zamora, Enrique Rodríguez and researchers from Zamora's group

\*\*\* Delegates will be assigned to a specific topic and receive the related evidence to be appraised before School attendance

### DAY 2

08:30–10:30	Plenary: Work discussed by each group in the presence of the full faculty for shared discussion: Groups 1 to 3
10:30–11:00	Coffee break
11:00–12:30	Plenary: Work discussed by each group in the presence of the full faculty for shared discussion: Groups 4 to 5
12:30–13:15	State of the art lecture on "Reaching consensus in cirrhosis and portal hypertension: evidence-based approach" – Faculty TBD
13:15–13:45	Post-quiz, comments and student evaluation of the School
13:45–14:00	Prizes and concluding remarks

**Examples of potential controversial clinical areas for discussion**

(1 or 2 per group)

1. Compensated cirrhosis. Problems to be addressed: diagnosis of CSPH, prognostic meaning of CSPH, beta-blockers in CSPH (varices vs. high LSM)
2. Decompensated cirrhosis. Problems to be addressed: long-term albumin (evidence, vs. TIPS) in recurrent ascites, secondary and primary prophylaxis of SBP, beta-blockers in recurrent/refractory ascites
3. Portal vein thrombosis. Problems to be addressed (outside the liver transplantation setting): treatment (partial vs. complete, anticoagulation vs. follow-up), impact on survival (partial vs. complete), efficacy of anticoagulants, efficacy of DOACS
4. TIPS in (early) prevention of recurrence. Problems to be addressed: prognostic meaning of variceal bleeding ± ascites, TIPS for recurrent bleeding (evidence on variables to consider: ascites, bleeding while on NSBB), TIPS for recurrent ascites, prevention of encephalopathy
5. Etiological treatment: Problems to be addressed: defining cirrhosis regression and recompensation, methods to evaluate cirrhosis regression, value of HVPG in MAFLD cirrhosis, HCC surveillance after HCV treatment.